# Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients

> **NCT07568041** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Cenna Biosciences Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** 8M2D
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07568041
- **Lead sponsor:** Cenna Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07568041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07568041, "Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07568041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*